Melanoma found in the lungs is almost always cancer that started somewhere else, most often the skin, and traveled through the bloodstream. True primary melanoma originating within lung tissue is extraordinarily rare, accounting for an estimated 0.01% of all primary lung tumors.1PubMed Central. Pulmonary metastatic melanoma: current state of diagnostic imaging and treatments What makes the lungs such a frequent landing spot for melanoma cells involves a surprisingly active biological process, one that recent genomic work has forced researchers to rethink from the ground up.
Why Melanoma Cells Home In on the Lungs
Melanoma does not spread to the lungs by accident. Cancer cells that break away from a skin tumor enter the bloodstream and circulate through the entire body, but they show a clear preference for certain organs. The lungs are one of the most common destinations, and a big reason comes down to molecular signaling. Melanoma cells that express a receptor called CXCR4 on their surface are drawn toward tissues that produce the matching chemical signal. Lung tissue produces this signal in abundance, essentially attracting circulating melanoma cells the way a lighthouse draws ships. In mouse experiments, melanoma cells engineered to overexpress CXCR4 produced more than a tenfold increase in lung metastases compared to control cells, and blocking the receptor with a small peptide completely stopped the increase.2PubMed. Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells
CXCR4 is not the whole story. Once a melanoma cell arrives in the lung’s tiny blood vessels, it still needs to break through the vessel wall and invade the surrounding tissue. A protein called MT1-MMP handles much of this work, acting like molecular scissors that cut through the tissue barrier. Research has shown that CXCR4 and MT1-MMP work as a coordinated team: CXCR4 guides the cells to the lungs in the early phase, while MT1-MMP takes over to help them invade and establish themselves afterward.3PubMed Central. The chemokine receptor CXCR4 and the metalloproteinase MT1-MMP are mutually required during melanoma metastasis to lungs Beyond these two players, a broader toolkit of adhesion molecules, enzymes, chemokines, and growth factors regulates how melanoma cells exit the bloodstream and take hold in a new organ.4PubMed Central. Current concepts of metastasis in melanoma
How the Lungs Get Prepared Before Cancer Cells Even Arrive
One of the more unsettling discoveries in recent cancer biology is that tumors can remodel distant organs ahead of time, turning them into more hospitable environments for incoming cancer cells. Melanoma tumors release tiny membrane-bound particles called exosomes into the bloodstream. These exosomes carry molecular cargo that travels to the lungs and other organs, where they reshape the local tissue environment, suppressing some immune responses and attracting supportive cell types, in effect rolling out a welcome mat for future metastases.5PubMed Central. The Key Role of Exosomes on the Pre-metastatic Niche Formation in Tumors
Interestingly, not all exosomes do the same thing. Research comparing exosomes from highly metastatic and non-metastatic melanoma cells found that exosomes from non-metastatic cells actually triggered a protective immune response. In mice, these exosomes were taken up by immune cells in the bone marrow and caused an expansion of patrolling monocytes, a type of immune cell that travels to the lungs and helps detect and clear arriving cancer cells. In contrast, exosomes from metastatic melanoma did not trigger this response, which may explain part of why aggressive melanomas succeed in seeding the lungs while less aggressive ones do not.6Nature Communications. Pre-metastatic cancer exosomes induce immune surveillance by patrolling monocytes at the metastatic niche
The Role of Lung Inflammation
The lungs are not passive recipients of cancer cells. Their local inflammatory state matters. Research has identified an anti-inflammatory protein called DEL-1 that is naturally abundant in healthy lung tissue. When DEL-1 levels drop, whether from infection, chronic irritation, or other inflammatory triggers, the lungs become significantly more vulnerable to melanoma colonization. The mechanism appears to involve neutrophils, a type of white blood cell. Without enough DEL-1 to keep them in check, neutrophils accumulate in the lung, creating an inflammatory environment that paradoxically helps tumor cells survive and grow while suppressing the natural killer cells that would normally destroy them.7PubMed Central. Endogenous DEL-1 restrains melanoma lung metastasis by limiting myeloid cell-associated lung inflammation
Neutrophils play a more direct accomplice role, too. When melanoma cells first get trapped in the lung’s narrow blood vessels, many of them die or get flushed out within hours. But melanoma cells produce a chemical signal called IL-8 that attracts nearby neutrophils. Once neutrophils arrive, they physically tether to the cancer cells using adhesion molecules, anchoring them in place against the vessel wall. In mouse experiments, injecting neutrophils an hour after tumor cells roughly tripled the number of cancer cells that stayed lodged in the lungs.8AACR Journals (Cancer Research). Transiently Entrapped Circulating Tumor Cells Interact with Neutrophils to Facilitate Lung Metastasis Development The result is counterintuitive: immune cells that normally fight infection end up helping cancer cells survive in a new organ.
The UV Signature That Rewrote the Textbook
For decades, doctors recognized a rare condition they called primary pulmonary melanoma, a melanoma that seemed to originate inside the lung itself with no skin tumor found anywhere on the body. The idea was not unreasonable: melanocytes, the pigment-producing cells that give rise to melanoma, do exist in small numbers within the airways. A set of strict diagnostic criteria required that no melanoma be found outside the chest, that the lung contain a solitary tumor, and that pathology show specific features including invasion of the bronchial lining.9PubMed Central. Primary Pulmonary Malignant Melanoma: Report of an Important Entity and Literature Review
A genomic study published in Modern Pathology examined tumors from patients who met these strict criteria for primary pulmonary melanoma and ran them through detailed genetic sequencing. The results were striking. Nearly all of the tumors carried a UV mutational signature, a distinctive pattern of DNA damage caused by ultraviolet radiation. Since UV light cannot reach the inside of the lungs, these mutations almost certainly originated in the skin. The tumors also carried the same types of driver mutations found in cutaneous melanoma, including changes in BRAF, NRAS, NF1, KIT, and KRAS, with an average mutation burden consistent with sun-exposed skin tumors.10Modern Pathology. Lung-only melanoma: UV mutational signature supports origin from occult cutaneous primaries and argues against the concept of primary pulmonary melanoma
The conclusion was direct: even when no skin melanoma can be found, lung melanoma most likely started as a small cutaneous tumor that either regressed on its own or was too small to detect, and then silently spread to the lungs. The researchers argued that lung-only melanoma should be considered metastatic by default, even without a known primary site.11Modern Pathology. Lung-only melanoma: UV mutational signature supports origin from occult cutaneous primaries and argues against the concept of primary pulmonary melanoma – Section: Discussion
When No Skin Tumor Can Be Found
The idea that a skin melanoma can vanish while its metastasis survives sounds strange, but it happens more often than people realize. Skin melanomas can be attacked and destroyed by the body’s immune system through a process called spontaneous regression. The original mole or lesion fades away or disappears entirely, but by the time it does, cancer cells have already escaped into the bloodstream. A patient might visit a doctor with a lung mass and no history of skin cancer, prompting a long and thorough search for a primary tumor that may no longer exist.
This phenomenon explains one of the enduring puzzles in melanoma oncology. Cases classified as “primary pulmonary melanoma” have trickled into the literature over the past century, but they remain extremely few, and each time genomic tools have been applied, the evidence has pointed back to a cutaneous origin. The practical upshot for patients is that a melanoma diagnosis in the lung should prompt a careful whole-body skin exam and imaging, but the absence of a visible skin lesion does not mean the cancer started in the lung.
Different Melanoma Subtypes, Different Routes to the Lungs
Skin melanoma is not the only type that can reach the lungs. Uveal melanoma, which arises in the eye, has its own biology and its own metastatic preferences, but the lungs are still a common destination. A mouse model of uveal melanoma driven by the GNAQ oncogene found that 94% of mice developed pigmented lung tumors within three months. Researchers observed melanoma cells extending from eye tumors toward blood vessels and invading vessel walls, a direct demonstration of how these cells enter the circulation and colonize distant organs.12Cancer Research. Oncogenic G Protein GNAQ Induces Uveal Melanoma and Intravasation in Mice
Mucosal melanoma, which develops in the lining of the mouth, nasal passages, rectum, or genitourinary tract, can also spread to the lungs. The cause of mucosal melanoma itself remains largely unknown, and unlike skin melanoma, UV exposure plays little to no role.13SpringerLink. Mucosal Melanoma: a Literature Review These tumors tend to be diagnosed at a more advanced stage because they grow in hidden locations, which means lung metastases may already be present by the time the primary is found. For both uveal and mucosal melanoma, the molecular pathways guiding cells to the lungs overlap with those seen in cutaneous melanoma, including the CXCR4-driven homing mechanism, but the driver mutations are often quite different, which has implications for treatment.
Why Lung Melanoma Gets Mistaken for Lung Cancer
Melanoma in the lung can look remarkably like a primary lung cancer on imaging and even under the microscope. A solitary lung mass in a patient with no known history of melanoma will initially be assumed to be lung carcinoma, which is vastly more common. Pathologists rely on a panel of immunohistochemical stains to tell the two apart. Melanoma cells typically stain positive for markers like HMB45, MelanA, and S-100, while lung cancers do not. Encouragingly, these markers are highly specific: a large study of non-small cell lung cancer samples found that HMB45 and MelanA were positive in fewer than 1% and 0% of cases, respectively.14PubMed Central. Expression of HMB45, MelanA and SOX10 is rare in non-small cell lung cancer That makes these stains reliable at confirming melanoma when the clinical picture is ambiguous.
Still, misdiagnosis happens. Solitary melanoma nodules, particularly the large, epithelioid-looking ones, can closely mimic the appearance of primary lung carcinomas and lead clinicians down the wrong treatment path before the correct diagnosis is reached.11Modern Pathology. Lung-only melanoma: UV mutational signature supports origin from occult cutaneous primaries and argues against the concept of primary pulmonary melanoma – Section: Discussion The distinction matters enormously because the treatments are different. Melanoma responds to immunotherapy drugs and targeted therapies aimed at specific mutations, while standard lung cancer chemotherapy regimens are unlikely to help. A biopsy that includes the right immunohistochemical stains is critical any time a lung mass appears in someone with even a remote history of melanoma or an atypical-looking tumor.
Genetic Predisposition and the BAP1 Connection
Most melanoma risk factors are environmental: UV exposure, fair skin, a history of sunburns. But inherited genetics play a role too, and one gene in particular has drawn attention for its connection to both melanoma and the lungs, though not in the way you might expect. Germline mutations in a tumor suppressor gene called BAP1 have been linked to a hereditary cancer syndrome that predisposes people to uveal melanoma, meningioma, and lung adenocarcinoma.15PubMed Central. Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers
This is not a case of melanoma spreading to the lungs; rather, it is a shared genetic vulnerability that raises the risk of developing separate cancers in both locations. Families carrying BAP1 mutations can see clusters of uveal melanoma, skin melanoma, kidney cancer, and lung cancer across generations. For someone diagnosed with uveal melanoma and found to carry a BAP1 mutation, the lungs become a site of concern for two different reasons: the possibility of metastatic spread from the eye and the independent risk of a new primary lung cancer. Screening recommendations for BAP1 carriers are still evolving, but awareness of this dual risk is growing among oncologists and genetic counselors who manage these families.
What Treatment Looks Like for Melanoma in the Lungs
The treatment approach for melanoma in the lungs depends heavily on whether the disease is limited to one or a few spots or widely spread. For a patient with a solitary metastasis and no other detectable disease, surgical removal of the lung lesion can sometimes be curative or at least extend survival significantly. This is especially true when the interval between treating the original skin melanoma and the appearance of the lung tumor is long, which tends to signal a less aggressive cancer biology.
For more widespread disease, systemic therapy is the backbone. Immunotherapy drugs that block the PD-1 or CTLA-4 checkpoints have transformed outcomes for metastatic melanoma over the past decade, and they work regardless of which organ the metastases are in. For tumors with certain targetable mutations, particularly BRAF, targeted therapy with BRAF and MEK inhibitors can produce rapid responses. The genomic profiling described earlier, looking at which driver mutations the tumor carries, directly informs which drugs are most likely to help. Identifying fusions and unusual alterations in BRAF or related genes can sometimes open the door to less common targeted agents as well.16PubMed Central. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy
The prognosis for melanoma that has metastasized to the lungs is generally better than for melanoma in the brain or liver, though it still represents advanced disease. Before modern immunotherapy, median survival for stage IV melanoma with lung metastases was measured in months. Current immunotherapy combinations have pushed five-year survival rates into ranges that were unthinkable two decades ago, though individual outcomes vary widely depending on tumor burden, mutation profile, and overall health. The lungs also remain easier to monitor with routine CT scans than some other metastatic sites, which helps catch recurrences early.
Smoking and Melanoma Lung Metastasis
A common question is whether smoking plays a role in melanoma reaching the lungs. Smoking is the overwhelming risk factor for primary lung cancers like adenocarcinoma and squamous cell carcinoma, so it is natural to wonder whether it affects melanoma metastasis too. The relationship is indirect but potentially meaningful. Chronic smoking causes persistent low-grade inflammation in lung tissue, damages the protective lining of the airways, and alters the local immune environment. All of these changes align with the mechanisms that make lungs hospitable to arriving melanoma cells, including neutrophil accumulation, reduced natural killer cell activity, and a pro-inflammatory microenvironment. While no large trial has established smoking as a direct risk factor for melanoma lung metastasis specifically, the biology strongly suggests that an already-inflamed lung is a more vulnerable one. For melanoma patients, this adds yet another reason to the long list of reasons not to smoke.